Literature DB >> 16690197

Crystal structures of GMP kinase in complex with ganciclovir monophosphate and Ap5G.

G Hible1, P Daalova, A-M Gilles, J Cherfils.   

Abstract

Guanosine monophosphate kinases (GMPK), by catalyzing the phosphorylation of GMP or dGMP, are of dual potential in assisting the activation of anti-viral prodrugs or as candidates for antibiotic strategies. Human GMPK is an obligate step for the activation of acyclic guanosine analogs, such as ganciclovir, which necessitate efficient phosphorylation, while GMPK from bacterial pathogens, in which this enzyme is essential, are potential targets for therapeutic inhibition. Here we analyze these two aspects of GMPK activity with the crystal structures of Escherichia coli GMPK in complex with ganciclovir-monophosphate (GCV-MP) and with a bi-substrate inhibitor, Ap5G. GCV-MP binds as GMP to the GMP-binding domain, which is identical in E. coli and human GMPKs, but unlike the natural substrate fails to stabilize the closed, catalytically-competent conformation of this domain. Comparison with GMP- and GDP-bound GMPK structures identifies the 2'hydroxyl of the ribose moiety as responsible for hooking the GMP-binding domain onto the CORE domain. Absence of this hydroxyl in GCV-MP impairs the stabilization of the active conformation, and explains why GCV-MP is phosphorylated less efficiently than GMP, but as efficiently as dGMP. In contrast, Ap5G is an efficient inhibitor of GMPK. The crystal structure shows that Ap5G locks an incompletely closed conformation of the enzyme, in which the adenine moiety is located outside its expected binding site. Instead, it binds at a subunit interface that is unique to the bacterial enzyme, which is in equilibrium between a dimeric and an hexameric form in solution. This suggests that inhibitors could be designed to bind at this interface such as to prevent nucleotide-induced domain closure. Altogether, these complexes point to domain motions as critical components to be evaluated in therapeutic strategies targeting NMP kinases, with opposite effects depending on whether efficient phosphorylation or inhibition is being sought after.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690197     DOI: 10.1016/j.biochi.2006.04.002

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  6 in total

1.  Solution structure and functional investigation of human guanylate kinase reveals allosteric networking and a crucial role for the enzyme in cancer.

Authors:  Nazimuddin Khan; Parag P Shah; David Ban; Pablo Trigo-Mouriño; Marta G Carneiro; Lynn DeLeeuw; William L Dean; John O Trent; Levi J Beverly; Manfred Konrad; Donghan Lee; T Michael Sabo
Journal:  J Biol Chem       Date:  2019-06-14       Impact factor: 5.157

2.  PharmGKB summary: acyclovir/ganciclovir pathway.

Authors:  Maud Maillard; Li Gong; Rina Nishii; Jun J Yang; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2022-05-30       Impact factor: 2.000

3.  Development of an HPLC-based guanosine monophosphate kinase assay and application to Plasmodium vivax guanylate kinase.

Authors:  Liliana Pedro; Megan Cross; Andreas Hofmann; Tin Mak; Ronald J Quinn
Journal:  Anal Biochem       Date:  2019-03-31       Impact factor: 3.365

4.  FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2.

Authors:  Alina Renz; Lina Widerspick; Andreas Dräger
Journal:  Bioinformatics       Date:  2020-12-30       Impact factor: 6.937

5.  Whole-body metabolic modelling predicts isoleucine dependency of SARS-CoV-2 replication.

Authors:  Ines Thiele; Ronan M T Fleming
Journal:  Comput Struct Biotechnol J       Date:  2022-07-20       Impact factor: 6.155

6.  Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target.

Authors:  Alina Renz; Lina Widerspick; Andreas Dräger
Journal:  Genes (Basel)       Date:  2021-05-24       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.